Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review

Souparnika, S; Nagarajan, Usharani; Natarajan, Sendhil Kumar

doi:10.1016/j.ijbiomac.2023.125022

International Journal of Biological Macromolecules

2023

DOI: 10.1016/j.ijbiomac.2023.125022

|View full text |Cite

Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review

S Souparnika

Usharani Nagarajan

Sendhil Kumar Natarajan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent Advancements in Benzothiazinones (BTZ) Analogs as DprE1 Inhibitor for Potent Antitubercular Therapeutics

Sonawane,

Said,

Lele

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Benzothiazinone analogs have emerged as a promising class of compounds having potent antimycobacterial activity, particularly against Mycobacterium tuberculosis, the pathogen responsible for tuberculosis. This review highlights the development of benzothiazinone analogs as potential antitubercular agents from the beginning to the recent advancement in the past decade. These compounds have shown potent activity, including drug‐resistant strains of Mycobacterium tuberculosis. Structure–activity relationship studies and modifications have improved their efficacy. Benzothiazinone analogs have favorable pharmacokinetic profiles and show promise in preclinical studies. Challenges include addressing resistance mechanisms and ensuring safety. Their unique mode of action and promising properties make them attractive candidates for the battle against drug‐resistant tuberculosis.

show abstract

Recent Advancements in Benzothiazinones (BTZ) Analogs as DprE1 Inhibitor for Potent Antitubercular Therapeutics

Sonawane,

Said,

Lele

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

show abstract

Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria

Sterle,

Habjan,

Piga

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

An eco friendly approach for the development of a dipeptide based anti-TB drug nanocomposites: A greener approach in drug delivery system for pulmonary delivery

Nagarajan,

Kanth

et al. 2024

Sustainable Materials and Technologies

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review

Cited by 6 publications

References 131 publications

Recent Advancements in Benzothiazinones (BTZ) Analogs as DprE1 Inhibitor for Potent Antitubercular Therapeutics

Recent Advancements in Benzothiazinones (BTZ) Analogs as DprE1 Inhibitor for Potent Antitubercular Therapeutics

Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria

An eco friendly approach for the development of a dipeptide based anti-TB drug nanocomposites: A greener approach in drug delivery system for pulmonary delivery

Contact Info

Product

Resources

About